Page 3 - HFA Dateline 2020-2021 Special Issue
P. 3
IN THIS ISSUE
ARTICLES
Assisting, educating, and advocating COVID-19 Vaccines
for the bleeding disorders & Emerging Therapies
community since 1994.
Volume 22 • Issue 1 • Special Issue 2021 Informed Consent:
A Process, Not
EXECUTIVE LEADERSHIP
Board Chair • Allie Ritchey Just A Form
President & CEO • Dr. Sharon
Meyers, CFRE
FDA's Gene
PRODUCTION TEAM and Cell Therapy
Editor • Kyle McKendall
Design & Layout • Ashley Williams Framework
Proofreader • Melanie Padgett
Powers
Drug Recall
Contributing Writers
Michael Bishop, HFA Staff Process & Recent
Dr. David Clark Product Recalls
Dr. Lisa Hensley
Angela N. Johnson, PH.D
Lori Long, HFA Staff Drug Approval Process
Emily Roush-Bobolz, HFA Staff
Sonji Wilkes, HFA Staff
The information printed in Clinical Studies:
Dateline Federation is provided How Do They
for general purpose use. HFA does Work?
not give medical advice or engage
in the practice of medicine and
recommends that you consult with your
physician or local treatment center
before beginning any form of treatment.
Requests for permission to translate
or reprint contents of Dateline FEATURES
Federation should be directed to
info@hemophiliafed.org.
Current
999 N. Capitol Street NE • Suite 301
Washington, DC 20002 Products
202.675.6984
info@hemophiliafed.org for Treament
©2021 Hemophilia Federation of America. Emerging
All rights reserved.
Therapies
Connect with us on social media Undergoing
for daily posts and updates about Clinical Trails
what’s happening at HFA.
SPECIAL ISSUE 2021 3